Alexandra D Carides
Overview
Explore the profile of Alexandra D Carides including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
928
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Warr D, Grunberg S, Gralla R, Hesketh P, Roila F, de Wit R, et al.
Eur J Cancer
. 2005 Jun;
41(9):1278-85.
PMID: 15939263
In this work, data from two phase III studies were pooled to further evaluate the NK(1) antagonist aprepitant for prevention of cisplatin induced nausea and vomiting. One thousand and forty...
12.
Pendergrass K, Hargreaves R, Petty K, Carides A, Evans J, Horgan K
Drugs Today (Barc)
. 2004 Dec;
40(10):853-63.
PMID: 15605119
This paper reviews the clinical profile of aprepitant, the first neurokinin-1 (NK(1)) receptor antagonist to be approved for use in the prevention of chemotherapy-induced nausea and vomiting. When given to...
13.
Hesketh P, Grunberg S, Gralla R, Warr D, Roila F, de Wit R, et al.
J Clin Oncol
. 2003 Oct;
21(22):4112-9.
PMID: 14559886
Purpose: In early clinical trials with patients receiving highly emetogenic chemotherapy, the neurokinin antagonist aprepitant significantly enhanced the efficacy of a standard antiemetic regimen consisting of a type-three 5-hydroxytryptamine antagonist...
14.
Poli-Bigelli S, Rodrigues-Pereira J, Carides A, Ma G, Eldridge K, Hipple A, et al.
Cancer
. 2003 Jun;
97(12):3090-8.
PMID: 12784346
Background: Aprepitant is a novel neurokinin 1 (NK(1)) antagonist that has been shown to improve control of chemotherapy-induced nausea and vomiting (CINV) when added to a standard antiemetic regimen of...
15.
Chawla S, Grunberg S, Gralla R, Hesketh P, Rittenberg C, Elmer M, et al.
Cancer
. 2003 Apr;
97(9):2290-300.
PMID: 12712486
Background: The neurokinin-1 antagonist aprepitant (EMEND; Merck Research Laboratories, West Point, PA) has been shown to reduce chemotherapy-induced nausea and vomiting when it is given with a 5-hydroxytryptamine-3 receptor antagonist...
16.
Van Belle S, Lichinitser M, Navari R, Garin A, Decramer M, Riviere A, et al.
Cancer
. 2002 Jul;
94(11):3032-41.
PMID: 12115394
Background: Recent studies have suggested that antiemetic therapy with a triple combination of the neurokinin-1 receptor antagonist MK-869, a serotonin (5-HT(3)) antagonist, and dexamethasone provides enhanced control of cisplatin-induced emesis...